» Articles » PMID: 23635779

Lung Tumor NF-κB Signaling Promotes T Cell-mediated Immune Surveillance

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2013 May 3
PMID 23635779
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

NF-κB is constitutively activated in many cancer types and is a potential key mediator of tumor-associated inflammation, tumor growth, and metastasis. We investigated the role of cancer cell NF-κB activity in T cell-mediated antitumor responses. In tumors rendered immunogenic by model antigen expression or following administration of antitumor vaccines, we found that high NF-κB activity leads to tumor rejection and/or growth suppression in mice. Using a global RNA expression microarray, we demonstrated that NF-κB enhanced expression of several T cell chemokines, including Ccl2, and decreased CCL2 expression was associated with enhanced tumor growth in a mouse lung cancer model. To investigate NF-κB function in human lung tumors, we identified a gene expression signature in human lung adenocarcinoma cell lines that was associated with NF-κB activity level. In patient tumor samples, overall lung tumor NF-κB activity was strongly associated with T cell infiltration but not with cancer cell proliferation. These results therefore indicate that NF-κB activity mediates immune surveillance and promotes antitumor T cell responses in both murine and human lung cancer.

Citing Articles

NF-κB-mediated EAAT3 upregulation in antioxidant defense and ferroptosis sensitivity in lung cancer.

Wen D, Li W, Song X, Hu M, Liao Y, Xu D Cell Death Dis. 2025; 16(1):124.

PMID: 39987248 PMC: 11847022. DOI: 10.1038/s41419-025-07453-y.


NF-κB signaling and the tumor microenvironment in osteosarcoma: implications for immune evasion and therapeutic resistance.

Shi S, Ou X, Liu C, Li R, Zheng Q, Hu L Front Immunol. 2025; 16:1518664.

PMID: 39949765 PMC: 11821961. DOI: 10.3389/fimmu.2025.1518664.


Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors.

Shi Y, McKenery A, Dolan M, Mastri M, Hill J, Dommer A EMBO Rep. 2024; 26(2):521-559.

PMID: 39663510 PMC: 11772817. DOI: 10.1038/s44319-024-00333-0.


NF-κB signaling pathway in tumor microenvironment.

Cao Y, Yi Y, Han C, Shi B Front Immunol. 2024; 15:1476030.

PMID: 39493763 PMC: 11530992. DOI: 10.3389/fimmu.2024.1476030.


-activated promotes lung adenocarcinoma progression and inhibits CD4/CD8 T-cell infiltrations by targeting signaling pathway.

Pan C, Wang Z, Wang Q, Wang H, Deng X, Chen L Transl Lung Cancer Res. 2024; 13(9):2116-2138.

PMID: 39430326 PMC: 11484716. DOI: 10.21037/tlcr-24-50.


References
1.
Muthuswamy R, Berk E, Junecko B, Zeh H, Zureikat A, Normolle D . NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res. 2012; 72(15):3735-43. PMC: 3780565. DOI: 10.1158/0008-5472.CAN-11-4136. View

2.
Vallabhapurapu S, Karin M . Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009; 27:693-733. DOI: 10.1146/annurev.immunol.021908.132641. View

3.
Sharma S, Bell D, Settleman J, Haber D . Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007; 7(3):169-81. DOI: 10.1038/nrc2088. View

4.
Hayden M, Ghosh S . Signaling to NF-kappaB. Genes Dev. 2004; 18(18):2195-224. DOI: 10.1101/gad.1228704. View

5.
Jing H, Kase J, Dorr J, Milanovic M, Lenze D, Grau M . Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev. 2011; 25(20):2137-46. PMC: 3205584. DOI: 10.1101/gad.17620611. View